Zhejiang Taimei Medical Technology Co (FRA:A2V) WACC %:Data Outdated (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:A2V Zhejiang Taimei Medical Technology Co Ltd FRA:A2V
11 GF Score
Price €0.52
! 3 Warning Signs
View Full Analysis

What is Zhejiang Taimei Medical Technology Co WACC %?

Zhejiang Taimei Medical Technology Co FRA:A2V +0.97% 11 WACC % is Data Outdated as of Sep. 21, 2026. GuruFocus rates FRA:A2V with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 696 Healthcare Providers & Services companies, Zhejiang Taimei Medical Technology Co ranks worse than 72.99% on this metric.

As of today (2026-09-21), Zhejiang Taimei Medical Technology Co's weighted average cost of capital is Data Outdated%. Zhejiang Taimei Medical Technology Co's ROIC % is -24.52% (calculated using TTM income statement data). Zhejiang Taimei Medical Technology Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Zhejiang Taimei Medical Technology Co  (FRA:A2V) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Zhejiang Taimei Medical Technology Co's weighted average cost of capital is Data Outdated%. Zhejiang Taimei Medical Technology Co's ROIC % is -24.52% (calculated using TTM income statement data). Zhejiang Taimei Medical Technology Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Zhejiang Taimei Medical Technology Co WACC % Historical Data

* Premium members only.

The historical data trend for Zhejiang Taimei Medical Technology Co's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Taimei Medical Technology Co WACC % Chart

Zhejiang Taimei Medical Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
- - - 10.49 9.96

Zhejiang Taimei Medical Technology Co Quarterly Data
Dec22 Dec23 Mar24
WACC % - - -

FRA:A2V vs VEEV, BTSG, TEM: WACC % Comparison

For the Health Information Services subindustry, Zhejiang Taimei Medical Technology Co's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Taimei Medical Technology Co WACC % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Zhejiang Taimei Medical Technology Co's WACC % distribution charts can be found below:

* The bar in red indicates where Zhejiang Taimei Medical Technology Co's WACC % falls into.


FRA:A2V
11GF Score
Zhejiang Taimei Medical Technology Co Ltd FRA:A2V
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Taimei Medical Technology Co WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of Data Outdated mean?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a WACC % of Data Outdated as of Sep. 21, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Zhejiang Taimei Medical Technology Co and its competitors. Over the past decade, Zhejiang Taimei Medical Technology Co's WACC % has ranged from 10.02 to 10.84. According to the industry distribution chart, Zhejiang Taimei Medical Technology Co ranks #508 out of 696 companies in the Healthcare Providers & Services industry, placing it in the top 73%.
Is Zhejiang Taimei Medical Technology Co's WACC % too high?
Zhejiang Taimei Medical Technology Co's current WACC % is Data Outdated. Over the past 10 years, this metric has ranged from a low of 10.02 to a high of 10.84. Based on the distribution chart, Zhejiang Taimei Medical Technology Co ranks #508 out of 696 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Zhejiang Taimei Medical Technology Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Taimei Medical Technology Co's WACC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Zhejiang Taimei Medical Technology Co ranks #508 out of 696 companies for WACC %. This places Zhejiang Taimei Medical Technology Co in the lower half of its industry. The industry median WACC % is 8.44. Historically, Zhejiang Taimei Medical Technology Co's own WACC % has ranged from 10.02 to 10.84 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Healthcare Providers & Services company?
The median WACC % among Healthcare Providers & Services companies is 8.44, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Zhejiang Taimei Medical Technology Co and its competitors. For the Healthcare Providers & Services industry, the median WACC % is 8.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Taimei Medical Technology Co's current WACC % is Data Outdated. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Taimei Medical Technology Co stock overvalued right now?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a current WACC % of Data Outdated. The current WACC % is Data Outdated. Zhejiang Taimei Medical Technology Co's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Zhejiang Taimei Medical Technology Co (FRA:A2V), the current WACC % is Data Outdated as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zhejiang Taimei Medical Technology Co Business Description

Other Exchanges 02576:Hong Kong
Address 36 Changsheng South Road, 3rd Floor, Building 9, Smart Industry Innovation Park, Zhejiang Province, Jiaxing, CHN
Zhejiang Taimei Medical Technology Co Ltd is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitate research and development (R&D) and the commercialization of pharmaceuticals and medical devices. The software it offers is cloud-based, allowing users to access it from various devices at any time over the internet, without the need for software installation and maintenance on their devices. It has a geographical presence in Mainland China, the United States, Singapore, Korea, and Others.
11GF Score

Get the complete analysis for FRA:A2V

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52
Price